Related Experiment Video
Updated: Sep 20, 2025
A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
Targeting mitochondrial quality control for myocardial ischemia-reperfusion injury
Yuxuan He1, Sixu Ren1, Chenglin Liu2
1Department of Cardiovascular Surgery, The Second Hospital of Jilin University, Changchun 130000, China; Norman Bethune Second Clinical Medical College, Jilin University, Changchun 130000, China.
Insights
Mitochondrial quality control (MQC) is crucial for managing myocardial ischemia-reperfusion injury (MIRI). Targeting MQC offers potential therapeutic strategies to reduce heart damage after acute myocardial infarction (AMI) reperfusion.
Area of Science:
- Cardiovascular research
- Mitochondrial biology
- Cellular homeostasis
Background:
- Cardiovascular disease (CVD) is the leading cause of global mortality.
- Acute myocardial infarction (AMI) and subsequent ischemia-reperfusion injury (MIRI) pose significant clinical challenges.
- Mitochondria are vital for cardiac function and cellular energy during MIRI.
Purpose of the Study:
- To review the mechanisms of mitochondrial quality control (MQC) in MIRI.
- To explore the complex regulatory networks of MQC in the context of MIRI.
- To summarize potential MQC-targeted treatments for mitigating MIRI.
Main Methods:
- Literature review of MQC mechanisms at molecular, organelle, and cellular levels.
- Analysis of the regulatory network of MQC in MIRI.
- Synthesis of current research on therapeutic strategies targeting MQC for MIRI.
Main Results:
- MQC plays a critical role in maintaining cellular homeostasis during MIRI.
- Complex regulatory networks involving MQC influence MIRI outcomes.
- Several preclinical strategies targeting MQC show promise for mitigating MIRI.
Conclusions:
- MQC is a key factor in managing MIRI following AMI.
- Targeting MQC presents a promising avenue for novel therapeutic interventions.
- Further research is needed to bridge the gap between preclinical findings and clinical application for MQC-based therapies.
Abstract:
Cardiovascular disease (CVD) remains the leading global cause of mortality. Acute myocardial infarction (AMI) refers to acute myocardial ischemia resulting from thrombosis secondary to coronary atherosclerosis, which poses a major threat to human health. Clinically, timely revascularization (reperfusion) represents the basis of clinical treatment for AMI. However, secondary myocardial ischemia-reperfusion injury (MIRI) caused by reperfusion often exacerbates damage, representing a major challenge in clinical practice. Mitochondria represent essential organelles for maintaining cardiac function and cellular bioenergetics in MIRI. In recent years, the role of mitochondrial quality control (MQC) in maintaining cell homeostasis and mediating MIRI has been extensively studied. This review provides a concise overview of MQC mechanisms at the molecular, organelle, and cellular levels and their possible complex regulatory network in MIRI. In addition, potential treatment strategies targeting MQC to mitigate MIRI are summarized, highlighting the gap between current preclinical research and clinical transformation. Overall, this review provides theoretical guidance for further research and clinical translational studies.
